Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(5):347-348; doi:10.1093/jnci/96.5.347
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, M.
Related Collections
Right arrowRelated Resource
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Canadian Society Takes Position on Long-Term Hormone Therapy

Michael Smith

The first 10% of the full text of this article appears below.

The Canadian Cancer Society is urging women to avoid combined hormone replacement therapy (HRT) using estrogen plus progestin, except in cases where severe menopausal symptoms do not respond to other treatments, because, among other things, it increases breast cancer risk.

The society is the first to take such a clear position, according to Heather Logan, director of cancer control policy for the Canadian Cancer Society.

The group’s position drew immediate fire from Canada’s obstetricians and gynecologists, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Resource

Canadian Recommendation on Hormone Therapy
J Natl Cancer Inst 2004 96: 348. [Extract] [Full Text] [PDF]